Research

Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.
Investigator
- Joseph Shrager
Now accepting new patients View Details
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
Investigators
- Jeffrey Norton, MD
- Andrei Iagaru
Not accepting patients at this time View Details
JSP191 Antibody Targeting Conditioning in SCID Patients

A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody conditioning regimen, known as JSP191, in patients with Severe Combined Immune Deficiency undergoing blood stem cell transplantation

Now accepting new patients View Details
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

Now accepting new patients View Details
Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study

This research registry studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting Selective Internal Radiation-Spheres (SIR-spheres) in non-resectable (RESIN) liver tumor registry. The information generated will help doctors better understand treatment patterns involving Y90 therapy, gain additional insights in the long-term outcomes for patients, as well as guide future research for using Y90 therapy, especially for those conditions where data is currently very limited or lacking.
Investigator
- David S. Wang, MD
Now accepting new patients View Details
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Avelumab in combination with talazoparib will be investigated in patients with locally advanced or metastatic solid tumors with a BRCA or ATM defect.

Not accepting patients at this time View Details
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

The purpose of this research study is to see if recurrent prostate cancer can be identified using a special procedure called a positron emission tomography (PET) scan. PET/CT is used to describe information regarding the function, as well as location and size of a tumor.
Investigator
- Andrei Iagaru
Not accepting patients at this time View Details
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sensitive ovarian cancer, urothelial cancer (UC), and castration resistant prostate cancer (CRPC).
Investigator
- Melinda L. Telli, M.D.
Not accepting patients at this time View Details
68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer

This clinical trial studies gallium-68 (68Ga)-prostate specific membrane antigen (PSMA) (gallium Ga 68-labeled PSMA ligand Glu-urea-Lys[Ahx]) positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) in identifying prostate cancer that may have returned after a period of improvement (biochemical recurrence). 68Ga-PSMA is a radiopharmaceutical that localizes to a specific prostate cancer receptor, which can then be imaged by the PET/CT or PET/MRI scanner.
Investigators
Not accepting patients at this time View Details
Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors

This clinical trial studies how well yttrium-90 (Y90) glass microspheres positron emission tomography (PET)/computed tomography (CT) works in imaging patients with liver tumors . Images produced by PET/CT may provide better information about the distribution of particles, such as Y90 glass microspheres, delivered for selective internal radiation therapy (SIRT) as compared to regular medical care images useing technetium Tc-99m albumin-aggregated single photon emission computed tomography (SPECT)/CT images.
Investigators
- David S. Wang, MD
- Andrei Iagaru
Not accepting patients at this time View Details
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors

JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of JTX-2011 alone and in combination with nivolumab, ipilimumab, or pembrolizumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Investigator
- Sunil Arani Reddy
Not accepting patients at this time View Details
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy

This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high intensity focused ultrasound (HIFU) or high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer.
Investigator
- Andrei Iagaru
Not accepting patients at this time View Details
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
Investigators
- Melanie Lean
- Khalid Salaheldin, MD
Now accepting new patients View Details
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation.
Investigator
- Lori Muffly
Not accepting patients at this time View Details
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

This phase 2-3 trial studies the utility of 68-gallium (68Ga)-prostate-specific membrane antigen 11 (PSMA-11) positron emission tomography/magnetic resonance imaging (PET/MRI) to find tumors in patients with prostate cancer who are undergoing resection surgery for prostate cancer that is prognostically expected to spread quickly (intermediate-risk) or is likely to come back or spread (high-risk). Diagnostic procedures, such as PET/MRI, may help find and diagnose prostate cancer, and reveal out how far the disease has spread. Radioactive drugs, such as 68Ga-PSMA-11, may bind to tumor cells that have specific receptors, and may allow doctors to see smaller tumors than the standard of care contrast-enhanced computed tomography (CT) or MRI scan.
Investigator
- Andrei Iagaru
Not accepting patients at this time View Details
Yoga for Youth With IBD: a Pilot Feasibility Study

An 8-week yoga intervention to determine the feasibility and acceptability of yoga as a supplemental therapy in the management of inflammatory bowel disease in the adolescent population.
Investigator
- Ann Ming Yeh
Not accepting patients at this time View Details
90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL

To test a new way to approach hematopoietic stem cell transplantation for Relapsed or Resistant Non-Hodgkin's Lymphoma.
Investigators
Not accepting patients at this time View Details
5-Day Preoperative Radiation for Soft Tissue Sarcoma

The purpose of this study is to examine the safety and efficacy of an abbreviated course of preoperative radiation, given over five days, for patients with soft tissue sarcoma of the extremity, trunk or retroperitoneum. This is in contrast to standard preoperative radiation, which is given over 25 days.
Investigator
- Everett J. Moding, MD, PhD
Now accepting new patients View Details
3D Body Surface Modeling for Scoliosis Monitoring

This is a single center, prospective, non-randomized reproducibility study of the NSite device in patients undergoing evaluation for scoliosis. The NSite device is a pre-market, investigational device. The study will enroll 13 eligible patients, who will be scanned using the NSite device by 3 separate users in order to assess if the device generates similar results across users. This data will be used to support 510(k) submission.
Investigator
- Kali Tileston
Now accepting new patients View Details
64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)

The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with PSMA-negative biochemical recurrence of prostate cancer following definitive therapy.
Investigator
- Hong Song, MD, PhD
Not accepting patients at this time View Details

Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.

Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.

Clinical Trials

Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

This study will determine the effect of QPI-1007 on visual function in subjects with recent-onset NAION and assess the safety and tolerability of intravitreal injections of QPI-1007 in this population. This study will also evaluate the structural changes in the retina following administration of QPI-1007.
Investigators
Not accepting patients at this time View Details
Study to Assess the Efficacy and Safety of Raxone in LHON Patients

LEROS is an open-label interventional Phase IV study, designed to further assess the efficacy and safety of Raxone® in the long-term treatment of LHON patients.
Investigator
- Y. Joyce Liao, MD, PhD
Not accepting patients at this time View Details
Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

This study is designed as a double-masked, randomized, placebo-controlled, clinical study to evaluate the efficacy and safety of subcutaneous (SC) administration of RPh201 in participants with previous NAION. All participants enrolled in Cohort A of the study will have a documented history of NAION for at least 12 months and at most, five years prior to enrollment. Participants enrolled in Cohort B of the study will have a documented history of NAION for at least 6 months and at most, three years prior to enrollment.
Investigators
Not accepting patients at this time View Details

Other Trials that are accepting patients

Coming soon

Observational Studies

In addition to the treatment trials described on this page we are actively studying IIH, vision in Multiple Sclerosis, and other conditions. See research projects (link) for more details.

Tweets by MossLabStanford

Physiologically Based Markers of Idiopathic Intracranial Hypertension, Stanford University

Dr. Heather Moss

hemoss@stanford.edu

Permanent visual impairment due to papilledema, an optic neuropathy characterized by optic nerve swelling, occurs in approximately half of patients with IIH. There is a significant clinical need for non-invasive biomarkers that will advance diagnosis and management of IIH. The objective of my research is to establish physiologically based markers of retinal ganglion cell(RGC) function and retinal/cerebral vasculature as markers of IIH that detect abnormalities, monitor treatment and distinguish peripheral vision outcomes. I have demonstrated that retinal vein diameter changes over the course of disease. Through collaboration with Dr. Ali Alaraj, an endovascular neurosurgeon, we have defined characteristic changes in cerebral venous blood flow and pressure in IIH patients. Through collaboration with Dr. McAnany, a psychophysics expert, we have demonstrated alterations in objective markers of optic nerve function that correlate with other measures of disease in IIH patients. These results are laying the scientific and technical foundation for the development of these markers as clinical tools and clinical trial outcome measures. Furthermore, the results are advancing scientific understanding of the pathophysiology underlying papilledema and other optic neuropathies.

Risk factors for peri-operative vision loss, Stanford University, University of Illinois at Chicago

Dr. Heather Moss

hemoss@stanford.edu

Perioperative visual loss (POVL) is a devastating complication, with no known treatment or prevention, most commonly due to ischemic optic neuropathy (ION), and retinal arterial occlusion (RAO), and less commonly cortical blindness. We reported in 2009 that POVL had an estimated incidence of 3-10 cases/10,000 procedures in two of the highest volume surgical procedures.1 The resulting severe visual impairment costs > $27,000/y, or $675,000 during the estimated remainder of a middle-aged individual’s life from increased health care spending alone. Lost productivity costing > $250,000, and frequent litigation further increase costs. The emotional toll of sudden, unexpected visual loss is immeasurable. It is imperative to understand the risk factors for POVL in order to develop means to prevent these blinding complications. In collaboration with the University of Illinois at Chicago and University of Illinois at Chicago we are studying risk factors and developing a predictive model for perioperative visual loss (POVL) in spinal fusion and cardiac surgery.

Development of Portable Pupillometer

Megha Bindiganavale

mbindiga@stanford.edu

Pupil reactivity is an important clinical marker of optic nerve function. Quantitative pupillometry may offer advantages over the qualitative clinical pupil exam. Current commercial devices that provide this metric are cumbersome, expensive, and require operator expertise. Our goal is to configure and validate the use of a portable device to perform quantitative pupillometry. A portable pupillometer might be useful in a clinical and research setting for diagnosis and monitoring of optic neuropathies and neurological disease. Light stimulation and pupil recording protocols were implemented using the retEVAL commercial device and Lua programming language.

Modeling

Munam Wasi

munam@stanford.edu

Our goal is to build 3D geometric models of the eye from planar MRI imaging for finite element analysis. It is understood that one mechanism of disease/injury that translates from the brain to the eyes is high intracranial pressure, but it’s quite impossible to see what’s going on inside the head through conventional means, as post-mortem autopsies capture the eyes without forces acting upon them. MRI images allow us to take a snapshot in time and infer the forces acting upon an eye, in order to better understand disease progression and what actually defines normalcy. Ultimately we hope that these computational techniques can be married with other tools like OCT to build automated diagnostic systems and improve care through detection.

MS Study

Fareshta Khushzad

fkhush@stanford.edu

Our goal is to evaluate novel non-invasive eye imaging biomarkers, with a focus on blood vessels, and neurons, as potential surrogates of brain inflammation and degeneration. We hope to learn which quantitative retinal vessel metrics can be used to help characterize inflammation in patients with multiple sclerosis. The information is important as it will provide preliminary information to further investigate these metrics as biomarkers in future studies to determine retinal vessel markers as longitudinal markers of MS. This knowledge will eventually allow clinicians to easily and inexpensively characterize the inflammation in patients with MS to help preemptively treat patients and make better predictions on the prognosis of the disease.

ERG Study

Megh Patel, Fareshta Khushzad, Dr. Heather Moss

hemoss@stanford.edu

In clinical practice, diseases that affect the retina and optic nerve are monitored by subjective patient responses to visual stimuli. Electrophysiology tests provide objective markers of optic nerve and retina function that may compliment subjective measures of vision. This project aims to compare electrophysiological tests of optic nerve and retina function. We hope to learn if electrophysiological tests and pupil reactivity tests using different devices and different stimulation protocols are comparable and how they relate to subjective visual function measures.

Comparison of Myelin Oligodendrocyte Glycoprotein Optic Neuritis Clinical Presentation between different ethnicities.

Tanyatuth Padungkiatsagul

tpadung@stanford.edu

During this past decade immunological markers of optic neuritis have been identified and became a substantial addition to patient care. Myelin Oligodendrocyte Glycoprotein, a novel serology marker, has linked to a certain variant of optic neuritis. Literatures from different part of the world reports some discrepancy in clinical presentation and prognosis. Ethnicity could be an important underlying factor for this variation, Thus we are investigating in our multi-center cohort of Myelin Oligodendrocyte Glycoprotein Optic Neuritis(MOGON) combined with published literatures in order to discover potential clinical variation among different ethnicity.

Tweets by MossLabStanford

Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

Investigator

68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

Investigators

JSP191 Antibody Targeting Conditioning in SCID Patients

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study

Investigator

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

Investigator

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Investigator

68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer

Investigators

Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors

Investigators

JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors

Investigator

68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy

Investigator

Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

Investigators

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Investigator

68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

Investigator

Yoga for Youth With IBD: a Pilot Feasibility Study

Investigator

90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL

Investigators

5-Day Preoperative Radiation for Soft Tissue Sarcoma

Investigator

3D Body Surface Modeling for Scoliosis Monitoring

Investigator

64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)

Investigator

Other Trials that are accepting patients

Observational Studies